» Articles » PMID: 36419791

Genetically High Angiotensin-converting Enzyme Concentrations Causally Increase Asthma Risk: A Meta-analysis Using Mendelian Randomization

Overview
Specialty General Medicine
Date 2022 Nov 24
PMID 36419791
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This meta-analysis aimed to test the association of angiotensin-converting enzyme () gene I/D polymorphism with asthma risk and circulating ACE changes.

Methods: Public literature retrieval, publication selection, and information extraction were completed independently by two investigators. Effect-size values are expressed as odds ratios (ORs) or standardized mean differences (SMDs) with a 95% confidence interval (95% CI).

Results: Nineteen studies (2,888 patients and 9,549 controls) fulfilled the eligibility criteria. Overall investigations demonstrated that gene I/D polymorphism was significantly associated with asthma risk under allelic (OR, 95% CI: 1.26, 1.08 to 1.48), homozygous genotypic (1.50, 1.09 to 2.06), and recessive (1.53, 1.24 to 1.89) models with moderate heterogeneity ( statistic: 64% to 79%). Subsidiary investigations recorded that race, matched status, asthma diagnosis, sample size, and age possibly accounted for the existence of significant heterogeneity. Relative to carriers with the II genotype, those with the DD genotype, ID genotype, and the combination of DD and ID genotypes had significantly higher concentrations of circulating ACE (WMD: 3.13, 2.07, and 2.83 U/L, respectively, < 0.05). Adoption of Mendelian randomization analyses revealed that one unit increment in circulating ACE concentrations was found to be significantly associated with a 1.14-fold increased risk of asthma (95% CI: 1.02 to 4.24).

Conclusion: We provided strong meta-analytical evidence supporting the causal implication of high circulating ACE concentrations in the development of asthma.

Citing Articles

Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences.

Cazzola M, Page C, Hanania N, Calzetta L, Matera M, Rogliani P Drugs. 2024; 84(10):1251-1273.

PMID: 39327397 PMC: 11512905. DOI: 10.1007/s40265-024-02086-5.

References
1.
Lee J, Nordestgaard B, Dahl M . Elevated ACE activity is not associated with asthma, COPD, and COPD co-morbidity. Respir Med. 2009; 103(9):1286-92. DOI: 10.1016/j.rmed.2009.04.003. View

2.
Shao Z, Jin H, Sun H, Dong C, Xu B, Zhan L . Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to pediatric asthma: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2020; 21(2):1470320320923475. PMC: 7329185. DOI: 10.1177/1470320320923475. View

3.
Tong Y, Ye C, Ren X, Qiu Y, Zang Y, Xiong X . Exosome-Mediated Transfer of ACE (Angiotensin-Converting Enzyme) From Adventitial Fibroblasts of Spontaneously Hypertensive Rats Promotes Vascular Smooth Muscle Cell Migration. Hypertension. 2018; 72(4):881-888. DOI: 10.1161/HYPERTENSIONAHA.118.11375. View

4.
Bonnelykke K, Sleiman P, Nielsen K, Kreiner-Moller E, Mercader J, Belgrave D . A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat Genet. 2013; 46(1):51-5. DOI: 10.1038/ng.2830. View

5.
Chagani T, Pare P, Zhu S, Weir T, Bai T, Behbehani N . Prevalence of tumor necrosis factor-alpha and angiotensin converting enzyme polymorphisms in mild/moderate and fatal/near-fatal asthma. Am J Respir Crit Care Med. 1999; 160(1):278-82. DOI: 10.1164/ajrccm.160.1.9808032. View